From website www.micurx.com accessed 8/28/2017: "The MicuRx mission is to bring safer and effective antibacterial products for therapy of Gram-positive and Gram-negative infections to healthcare providers globally. In 2015, MicuRx reported successful results for its lead compound, MRX-1, from two oral Phase 2 studies in complicated skin and soft tissue infections, including methicillin-resistant Staphylococccus aureus (MRSA) infections, conducted in China and the USA. MRX-1 is currently in Phase 3 trials in China with additional clinical tests planned for the US."
Zhengyu Yuan, Ph.D.
President and Chief Executive Officer Dr. Yuan brings over 25 years of experience in drug discovery and development, with a strong expertise in research and development of novel antibiotics. He founded MicuRx to identify novel antibiotic and antifungal agents. Prior to MicuRx, Dr. Yuan was a founding scientist and senior vice president of research for Vicuron Pharmaceuticals Inc., through its successful acquisition by Pfizer. Previously, Dr. Yuan held a variety of senior management positions at Syntex, Affymax, and GlaxoWellcome. He received his Ph.D. in biochemistry from Cornell University and a B.S. degree in chemistry from Fudan University in Shanghai. Dr. Yuan has authored multiple patents and nearly 40 peer-reviewed publications.
Barry Hafkin, M.D.
Chief Medical Officer. An experienced physician specializing in adult infectious diseases and a seasoned executive with experience at both large pharma and small biotech companies, Dr. Hafkin brings the deep understanding of unmet medical needs facing patients and doctors dealing with life-threatening infections. Prior to MicuRx Pharmaceuticals, Dr. Hafkin served in executive roles at Nobelex, Affinium Pharmaceuticals (acquired by Debiopharm Group™), Cumbre Pharmaceuticals and Advancis Pharmaceuticals, where he was responsible for all aspects of pharmaceutical development, registration and marketing support. Prior to Advancis, he served as director of virology and immunology at Boehringer Ingelheim where he built the clinical trials team in virology and managed development for Aptivus® (tipranivir). Previously, he served as senior director and therapeutic area director for infectious diseases at Pharmacia where he led the global development of blockbuster agents Zyvox® (linezolid). Prior to Pharmacia, Dr. Hafkin maintained an infectious disease and epidemiology practice. He also served as a principal investigator for the Epidemic Intelligence Service of the Centers for Disease Control. He received his M.D. from the University of Texas Medical School in San Antonio and completed his infectious disease fellowship at Stanford University Medical Center.
Mike F. Gordeev, Ph.D.
Chief Scientific Officer. Dr. Gordeev co-founded MicuRx to apply his core expertise in medicinal chemistry with an emphasis on the design, identification, and IND-enablement of anti-infective agents. Prior to MicuRx, he was vice president of medicinal chemistry at Vicuron Pharmaceuticals Inc. where he led several major internal and big pharma collaborations that resulted in small molecule and natural product antibiotics. Prior to Vicuron, Mike held positions of increasing responsibility at GlaxoWellcome and Affymax. Previously, he served in scientific roles at Alan Katritzky’s Center for Heterocyclic Compounds at the University of Florida (Gainesville) and Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences (Moscow). Dr. Gordeev received his M.S. and Ph.D. in organic chemistry from Moscow State University. He has authored over 100 peer-reviewed publications and multiple issued patents.
San Francisco Bay Area Office, 3916 Trust Way, Hayward, CA 94545, (510) 782-2021
Shanghai Office, MicuRx Pharmaceuticals, Inc. (Shanghai), 720 Cailun Rd., Bldg. 2, Suite 401
Zhanjiang Hi-Tech Park, Pudong District, Shanghai, 20123 People’s Republic of China
Data presented at NIAID in confidential meeting 2017. Later posters presented at GRC June 2017 by Barry Hafkin on Phase 1 MRX-1 versus Linezolid and by Michael Cynamon on in vivo activity of MRX-1 in murine TB model